{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:52:49Z","timestamp":1792396369570,"version":"4.4.0"},"reference-count":78,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Blinatumomab is a CD19\u2009\u00d7\u2009CD3\u2010directed bispecific T\u2010cell engager that has become an essential backbone of acute B lymphoblastic leukaemia (BCP\u2010ALL) treatment. It is used in relapsed\/refractory disease, minimal residual disease (MRD), as well as in first\u2010line treatment. Blinatumomab is particularly effective in MRD\u2010positive BCP\u2010ALL, inducing a high rate of deep molecular response, with very good overall tolerability. Very promising data are reported for the addition of blinatumomab to first\u2010line therapy. This review focusses on new aspects of blinatumomab treatment in Philadelphia\u2010negative BCP\u2010ALL treatment in adult patients, including MRD\u2010positive and relapsed\/refractory disease, as well as reviewing recent clinical trials implementing blinatumomab into first\u2010line therapy of BCP\u2010ALL treatment.<\/jats:p>","DOI":"10.1111\/bjh.20134","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T22:45:11Z","timestamp":1747262711000},"page":"27-42","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of blinatumomab in adult acute B lymphoblastic leukaemia"],"prefix":"10.1111","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5813-267X","authenticated-orcid":false,"given":"Anne C.","family":"Wilke","sequence":"first","affiliation":[{"name":"Department of Medicine II, Department for Hematology\/Oncology Goethe University  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-8245","authenticated-orcid":false,"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Department for Hematology\/Oncology Goethe University  Frankfurt am Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1338270"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu089"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00063"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26634"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_2_14_14_1","unstructured":"ShahB MattisonRJ AbboudR AbdelmessiehP AldossI BurkePW et\u00a0al.NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) acute lymphoblastic leukemia [Internet]. Version 2.2024. July 19 2024. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023568"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32335"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33298"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.12.009"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2021.06.005"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649111"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16306"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27227"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201009\u2010377713"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010018\u20104670\u20105"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1709834"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.07.021"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13375"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137350"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-171751"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967372.19440.62"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146306"},{"key":"e_1_2_14_35_1","unstructured":"FDA granted accelerated approval to blinatumomab (Blincyto Amgen Inc.) for the treatment of adult and pediatric patients with B\u2010cell precursor acute lymphoblastic leukemia [Internet]. 2024. Available from:https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010granted\u2010accelerated\u2010approval\u2010blinatumomab\u2010blincyto\u2010amgen\u2010inc\u2010treatment\u2010adult\u2010and\u2010pediatric"},{"key":"e_1_2_14_36_1","unstructured":"GreenwoodM GangatharanS OsbornM NgA FlemingS FedeleP et\u00a0al.Blinatumomab as consolidation in a paediatric protocol leads to high rates of end\u2010consolidation MRD negativity and excellent outcomes in AYA ALL \u2013 final results of the ALLG ALL09 \u201cSUBLIME\u201d study. EHA Library. 2024; Abstract S112."},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174973"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146163"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138565"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00285-X"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19017"},{"key":"e_1_2_14_42_1","unstructured":"vanBaalenE GradowskaP BellidoM deWeerdtO GadisseurA DeerenD et\u00a0al.Blinatumomab added to prephase and consolidation therapy in adult B\u2010ALL: a comparison of the consecutive HOVON\u2010100 and H\u2010146 studies. EHA Library. 2024; Abstract S113."},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180472"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01766"},{"key":"e_1_2_14_45_1","doi-asserted-by":"crossref","unstructured":"WieduwiltM YinJ KourO TeskeR StockW ByrdK et\u00a0al.Chemotherapy\u2010free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly\u2010diagnosed Ph\u2010negative CD22\u2010positive B\u2010cell acute lymphoblastic leukemia: ALLIANCE A041703. EHA Library. 2023; Abstract S117.","DOI":"10.1097\/01.HS9.0000967380.08838.b7"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968372.81147.9d"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00073-X"},{"key":"e_1_2_14_48_1","unstructured":"JabbourE AldossI FlemingS BajelA CannellP Br\u00fcggemannM et\u00a0al.Blinatumomab alternating with low\u2010intensity chemotherapy (LIC) in older adults with newly diagnosed B\u2010cell acute lymphoblastic leukemia (ALL): safety run\u2010in follow\u2010up for the phase 3 Golden Gate study. EHA Library. 2024; Abstract P416."},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156080"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158934"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00546"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000018"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33967"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12357"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642466"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24783"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1181620"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201006\u2010651380"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173937"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001925"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32116"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147446"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19008"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154124"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642"},{"issue":"1","key":"e_1_2_14_78_1","first-page":"6","article-title":"Overview of approved CAR\u2010T therapies, ongoing clinical trials, and its impact on clinical practice","volume":"3","author":"Sengsayadeth S","year":"2021","journal-title":"EJHaem"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01379-0"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.20134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:19:27Z","timestamp":1765534767000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.20134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/bjh.20134"],"URL":"https:\/\/doi.org\/10.1111\/bjh.20134","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"2024-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}